+ Watch GALE
on My Watchlist
undervalued vs. potential, likely 10x in 5 years
Priced well beyond reality
I finally let go of my Galena outperform a few weeks ago after it had stagnated in the low 2's for months. The stock rewarded me by promptly embarking on a sharp upward tear that would have provided me another 150 CAPS points. What suddenly blasted the stock out of its recent trading range? I have no idea. There's never been any shortage of fawning SA articles, and the ones published around the time of the breakout don't seem particularly original or inspired. The recent earnings CC didn't seem to provide any surprising or positive information either. The PRESENT trial continues to enroll without an estimated time of completion, although Zacks has predicted enrollment would be complete before the end of 2013. Abstral is unlikely to be a game changer for Galena, and the cheaply acquired pain drug wasn't even launched until October. I even considered the possibility of an uncorking effect from the damage done to Feuerstein, the stock's greatest critic, by his surprising double faceplant on Vanda and Sarepta. However, it seems clear that the move in Galena began at least 10 days before Feuerstein's bad day. So like many a move in small cap biopharma stocks, this one will remain a mystery to me. Nevertheless, I'll go with my long-term view on the prospects of PRESENT and drop a red thumb for the eventual trial failure.
poised to go even higher - price target $6 - fasten the seat belt....
The reward potential here is massive with NeuVax on the horizon. Cash position should last a while, not to mention revenue from Abstral will help. Could be a multi-bagger, even from its current valuation at $4/share.
Most fledgling pharma stocks are wildly speculative, but the odds are getting better because1.GALE just got a $30+ million cash infusion. 2.Has promising products,one already well tested in Europe.This fool shortens his own odds by increasing leverage via GALE's 2012 fundraising security which involved creating some sexy warrants (so much beloved by Warren Buffett] Once GALE gets back to around 2.50 = that happened before = we are off to the races.GALE appears to me a good acquisition target by a Big Pharma = if so = our time frame shortens considerably.Then we fools can raise our glasses with the most expensive French bubbly..
Short. Biopharma. No revenues, they just issue more and more stock each year.
Ready for a turnaround
Teamed up with TEVA for the phase 3 drug trials. That's a solid endorsement.
High Volume breakout on 02/19/13
This stock wouldn't have gotten Teva Pharmaceuticals interested if the results weren't solid. I can't imagine this stock being lower than $2 for long. Great entry point right now!
Great time to buy. I don't see the stock getting much cheaper any time soon.
It was picked by www.hechtsoft.de Trade Alerts.
Drug NueVax in Phase III trials with very promising results for breast cancer.
Going long here----dropped on the Share Offerring/Dilution.
Chart Play + Long Play
Some real potential here long term for patients and investors alike."Save the Ta-tahs!"
Engaged in RNA targeted solutions and just received patent for very promising breast cancer drug (Neuvax) in phase III testing that may benefit 50-70% of breast cancer patients.
Biotech with good Insider buying and a solid candidate drug. Look for gains to $2 or more in the short-term.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions